title: The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome.
abstract: Bipolar disorder is a devastating illness that is marked by recurrent episodes of mania and depression. There is growing evidence that the disease is correlated with disruptions in synaptic plasticity cascades involved in cognition and mood regulation. Alleviating the symptoms of bipolar disorder involves chronic treatment with mood stabilizers like lithium or valproate. These two structurally dissimilar drugs are known to alter prominent signaling cascades in the hippocampus, but their effects on the post-synaptic density complex remain undefined. In this work, we utilized mass spectrometry for quantitative profiling of the rat hippocampal post-synaptic proteome to investigate the effects of chronic mood stabilizer treatment. Our data show that in response to chronic treatment of mood stabilizers there were not gross qualitative changes but rather subtle quantitative perturbations in post-synaptic density proteome linked to several key signaling pathways. Our data specifically support the changes in actin dynamics on valproate treatment. Using label-free quantification methods, we report that lithium and valproate significantly altered the abundance of 21 and 43 proteins, respectively. Seven proteins were affected similarly by both lithium and valproate: Ank3, glutamate receptor 3, dynein heavy chain 1, and four isoforms of the 14-3-3 family. Immunoblotting the same samples confirmed the changes in Ank3 and glutamate receptor 3 abundance. Our findings support the hypotheses that BPD is a synaptic disorder and that mood stabilizers modulate the protein signaling complex in the hippocampal post-synaptic density.
authors.affiliation: Laboratory of Neurotoxicology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1262, USA.
authors.forename: Dhaval
authors.initials: D
authors.lastname: Nanavati
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Austin
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Catapano
authors.forename: David A
authors.initials: DA
authors.lastname: Luckenbaugh
authors.forename: Ayse
authors.initials: A
authors.lastname: Dosemeci
authors.forename: Husseini K
authors.initials: HK
authors.lastname: Manji
authors.forename: Guang
authors.initials: G
authors.lastname: Chen
authors.forename: Sanford P
authors.initials: SP
authors.lastname: Markey
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D053263:Gene Regulatory Networks / Q000187:drug effects / Q000502:physiology; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism*; D008094:Lithium / Q000008:administration & dosage*; D008297:Male; D019964:Mood Disorders / Q000188:drug therapy; D057907:Post-Synaptic Density / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D020543:Proteome / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D011921:Rats, Inbred WKY; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage*
chemical_list: D014150:Antipsychotic Agents; D020543:Proteome; D014635:Valproic Acid; D008094:Lithium